Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer
Shanghai Zhongshan Hospital
Shanghai Zhongshan Hospital
Henan Cancer Hospital
Infinity Pharmaceuticals, Inc.
OncoSec Medical Incorporated
Tang-Du Hospital
Hunan Cancer Hospital
Zhejiang Cancer Hospital
First Affiliated Hospital Xi'an Jiaotong University
Tianjin Medical University Cancer Institute and Hospital
West China Hospital
Air Force Military Medical University, China
Ludwig-Maximilians - University of Munich
Second Affiliated Hospital, School of Medicine, Zhejiang University
First Affiliated Hospital Xi'an Jiaotong University
Henan Cancer Hospital
Taizhou EOC Pharma Co., Ltd.
IRCCS San Raffaele
Peking Union Medical College Hospital
ChineseAMS
Peking Union Medical College Hospital
CSPC Ouyi Pharmaceutical Co., Ltd.
Huazhong University of Science and Technology
Fujian Cancer Hospital
Australasian Gastro-Intestinal Trials Group
Fudan University
Sichuan Cancer Hospital and Research Institute
Second Affiliated Hospital, School of Medicine, Zhejiang University
Fudan University
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Tianjin Medical University Cancer Institute and Hospital
Benaroya Research Institute
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Shandong Cancer Hospital and Institute
Sichuan Cancer Hospital and Research Institute
Zhongshan Hospital Xiamen University
Fudan University
China Medical University, China
Zhejiang Cancer Hospital
Peking Union Medical College
Tongji Hospital
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Third Military Medical University
Peking Union Medical College
Henan Cancer Hospital
Harbin Medical University
Zhejiang Cancer Hospital
Zhejiang Cancer Hospital
Peking University
Ludwig-Maximilians - University of Munich
Atlantic Health System